Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 3/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13600008 | 0.85 | CA12 (0.42) | SCDCA12CA1CA2CA9 | |
| SCHEMBL13600045 | 0.84 | GABRP (0.43) | SCDDHODH | |
| SCHEMBL13600054 | 0.82 | SCD (0.38) | SCDDHODH | |
| SCHEMBL13600046 | 0.81 | GPR6 (0.42) | SCDGRM4 | |
| SCHEMBL13600174 | 0.81 | NAMPT (0.40) | CA12CA1CA2CA9EGFR | |
| SCHEMBL13607283 | 0.81 | GPR119 (0.46) | SCD | |
| SCHEMBL13600044 | 0.78 | FPR2 (0.34) | — | |
| SCHEMBL13600033 | 0.69 | CYP11B2 (0.39) | EGFR | |
| SCHEMBL13600058 | 0.69 | GPR6 (0.43) | GRM4EGFR | |
| SCHEMBL13600004 | 0.69 | MAPT (0.49) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638531-B2 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | HRH4, HRH3, HRH2 | SCD 1995/4885DHODH 1223/4885BACE1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.